Identification | Back Directory | [Name]
3-DEAZAADENOSINE | [CAS]
6736-58-9 | [Synonyms]
C3-Ado NSC 167897 3-Deaza-rA 3-DEAZAADENOSINE 3-Deaza-D-adenosine 3-Deazaadenosine ,98% 1-β-D-Ribofuranosyl-1H-imidazo[4,5-c]pyridin-4-amine 4-Amino-1-(D-ribofuranosyl)-1H-imidazo(4,5)-pyridine 4-Amino-1-beta-D-ribofuranosyl-1H-imidazo[4,5-c]pyridine 1H-Imidazo4,5-cpyridin-4-amine, 1-.beta.-D-ribofuranosyl- 4-AMINO-1-[BETA-D-RIBOFURANOSYL]-1H-IMIDAZO[4,5]-PYRIDINE (2R,3R,4S,5R)-2-(4-AMino-1H-iMidazo[4,5-c]pyridin-1-yl)-5-(hydroxyMethyl)tetrahydrofuran-3,4-diol | [Molecular Formula]
C11H14N4O4 | [MDL Number]
MFCD00153951 | [MOL File]
6736-58-9.mol | [Molecular Weight]
266.25 |
Chemical Properties | Back Directory | [Description]
3-Deazaadenosine (3-DZA) is an inhibitor of SAH (Sadenosylhomocysteine) hydrolase (Ki = 3.9 μM). It has antiinflammatory properties, inhibiting leukocyte adhesion and chemotaxis, lymphocyte-mediated cytolysis, phagocytosis, degranulation, and NF-κB signaling. 3-DZA also has anti-viral and anti-bacterial activities. | [Appearance]
Bright Yellow Solid | [Melting point ]
228-229°C | [Boiling point ]
665.7±65.0 °C(Predicted) | [density ]
1.90±0.1 g/cm3 (20 ºC 760 Torr) | [storage temp. ]
2-8°C
| [solubility ]
H2O: 10 mg/mL with heating to 60 °C
| [form ]
Solid | [pka]
13.24±0.70(Predicted) | [color ]
White to Off-White |
Hazard Information | Back Directory | [Chemical Properties]
Bright Yellow Solid | [Uses]
Possesses antiviral activity. It is an inhibitor of leukocyte adhesion to TNF-treated endothelial cells | [Biochem/physiol Actions]
Possesses antiviral activity inhibitor of leukocyte adhesion to TNF-treated endothelial cells. | [in vitro]
3-deazaadenosine showed inhibitory values against the ebo-z viruses, ebo, and marburg virus in various cell lines of primate (sw13, vero 76, frhl, llc-mk2, mrc-5, vero e6) and mouse (balb/3t3 clone a31) origin. 3-deazaadenosine at 2 μg/ml could reduce viral replication by 3 logs in a dose-dependent manner. however, there was no further inhibition even with a 100-fold increase in concentration [1]. | [in vivo]
in vehicle control group, adult balb/c mice lethally infected with mouse-adapted ebola virus die 5-7 days after infection. in contrast, 3-deazaadenosine treatment initiated on day 0 or 1 led to a dose-dependent protection, with mortality completely prevented at doses around 0.7 mg/kg every 8 h. moreover, there was significant protection when 3-deazaadenosine treatment was begun on day 2, at which time, the spleen had an average titer of 2 × 106 pfu/g and the liver had 3 × 105 pfu/g virus. treatment with 3-aeazaadenosine at 2.2 mg/kg initiated on day 3 resulted in 40% survival [1]. | [References]
[1] huggins, z. x. zhang and m. bray. antiretroviral drug therapy of filovirus infections: s-adenosylhomocysteine hydrolase inhibitors inhibit ebola virus in vitro and in a lethal mouse model. journal of infectious diseases 179 (1), s240-s247 (1999). |
|
|